Companies Intellia Therapeutics, Inc.
Intellia Therapeutics (NTLA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Intellia Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers39th pct.Of 20 peer CEOs
CEO pay, last three years
- $11,657,262FY2023
- $15,330,547FY2024
- $5,063,899FY2025
CEO total pay was $5,063,899 in fiscal 2025, down from $15,330,547 in fiscal 2024.
FY2025: salary $708,000 · bonus $529,230 · stock awards $2,443,920 · option awards $1,356,320
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Intellia Therapeutics, Inc. in fiscal 2025?
As disclosed, John Leonard (President, Chief Executive Officer) was the highest-paid executive at Intellia Therapeutics, Inc. in fiscal 2025, with total compensation of $5,063,899.
How does Intellia Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Leonard's total compensation ranked at the 39th percentile of Intellia Therapeutics, Inc.'s disclosed peer group.
What is Intellia Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Intellia Therapeutics, Inc.'s CEO-to-median employee pay ratio was 17:1.
How did shareholders vote on Intellia Therapeutics, Inc.'s executive compensation?
As disclosed, 76.43% of shareholders supported Intellia Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Intellia Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Intellia Therapeutics, Inc. reported total board compensation of $437,120 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Leonard | $708,000 | $529,230 | $2,443,920 | $1,356,320 | $0 | $0 | $26,429 | $5,063,899 |
| President, Chief Executive Officer | ||||||||
| Edward Dulac | 526,000 | 270,996 | 848,184 | 466,609 | 0 | 0 | 56,716 | 2,168,505 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| David Lebwohl | 536,000 | 234,232 | 776,304 | 427,061 | 0 | 0 | 11,127 | 1,984,724 |
| Executive Vice President, Chief Medical Officer | ||||||||
| James Basta | 494,000 | 227,240 | 718,800 | 395,430 | 0 | 0 | 11,127 | 1,846,597 |
| Executive Vice President, General Counsel and Corporate Secretary | ||||||||
| Birgit Schultes | 475,000 | 207,575 | 675,672 | 371,701 | 0 | 0 | 10,135 | 1,740,083 |
| Executive Vice President, Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Leonard | $5,063,899 | $15,330,547 | $11,657,262 | ↓ −10,266,648 |
| Edward Dulac | 2,168,505 | 6,694,737 | — | ↓ −4,526,232 |
| David Lebwohl | 1,984,724 | 5,577,407 | 4,257,962 | ↓ −3,592,683 |
| James Basta | 1,846,597 | 4,872,670 | 3,994,791 | ↓ −3,026,073 |
| Birgit Schultes | 1,740,083 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Intellia has implemented a pay-for-performance focused compensation program designed to motivate employees, including named executive officers, to achieve short- and long-term results that drive the Company's success and are in the best interests of stockholders.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | true |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Edward Dulac | PSU | 2025-03-01 | 11,800 | 23,600 | — | 47,200 | $371,936 |
| Edward Dulac | RSU | 2025-03-01 | — | — | 47,200 | — | 476,248 |
| David Lebwohl | RSU | 2025-03-01 | — | — | 43,200 | — | 435,888 |
| James Basta | PSU | 2025-03-01 | 10,000 | 20,000 | — | 40,000 | 315,200 |
| John Leonard | PSU | 2025-03-01 | 34,000 | 68,000 | — | 136,000 | 1,071,680 |
| Edward Dulac | OPTION | 2025-03-01 | — | — | 67,429 | — | 466,609 |
| Birgit Schultes | PSU | 2025-03-01 | 9,400 | 18,800 | — | 37,600 | 296,288 |
| David Lebwohl | PSU | 2025-03-01 | 10,800 | 21,600 | — | 43,200 | 340,416 |
| John Leonard | RSU | 2025-03-01 | — | — | 136,000 | — | 1,372,240 |
| James Basta | RSU | 2025-03-01 | — | — | 40,000 | — | 403,600 |
| Birgit Schultes | RSU | 2025-03-01 | — | — | 37,600 | — | 379,384 |
| John Leonard | OPTION | 2025-03-01 | — | — | 196,000 | — | 1,356,320 |
| James Basta | OPTION | 2025-03-01 | — | — | 57,143 | — | 395,430 |
| David Lebwohl | OPTION | 2025-03-01 | — | — | 61,714 | — | 427,061 |
| Birgit Schultes | OPTION | 2025-03-01 | — | — | 53,714 | — | 371,701 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Edward Dulac | $476,248 | $371,936 | $466,609 | 28.3% |
| David Lebwohl | 435,888 | 340,416 | 427,061 | 28.3% |
| James Basta | 403,600 | 315,200 | 395,430 | 28.3% |
| John Leonard | 1,372,240 | 1,071,680 | 1,356,320 | 28.2% |
| Birgit Schultes | 379,384 | 296,288 | 371,701 | 28.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Birgit Schultes | Option | 694 | 40.75 | — |
| James Basta | Option | 964 | 40.75 | — |
| David Lebwohl | Option | 1,204 | 40.75 | — |
| John Leonard | Option | 3,574 | 40.75 | — |
| Birgit Schultes | PSU | 4,417 | — | 39,709 |
| Birgit Schultes | PSU | 5,511 | — | 49,544 |
| Birgit Schultes | RSU | 5,890 | — | 52,951 |
| James Basta | PSU | 6,135 | — | 55,154 |
| David Lebwohl | PSU | 7,669 | — | 68,944 |
| James Basta | PSU | 8,099 | — | 72,810 |
| Birgit Schultes | PSU | 9,400 | — | 84,506 |
| David Lebwohl | PSU | 9,675 | — | 86,978 |
| James Basta | PSU | 10,000 | — | 89,900 |
| David Lebwohl | RSU | 10,226 | — | 91,932 |
| David Lebwohl | PSU | 10,800 | — | 97,092 |
| Birgit Schultes | Option | 11,490 | 32.66 | — |
| Edward Dulac | PSU | 11,800 | — | 106,082 |
| James Basta | RSU | 12,271 | — | 110,316 |
| Birgit Schultes | RSU | 14,697 | — | 132,126 |
| Birgit Schultes | PSU | 15,309 | — | 137,628 |
| Edward Dulac | PSU | 16,581 | — | 149,063 |
| James Basta | Option | 16,883 | 32.66 | — |
| David Lebwohl | Option | 20,171 | 32.66 | — |
| James Basta | RSU | 21,596 | — | 194,148 |
| John Leonard | PSU | 22,759 | — | 204,603 |
| David Lebwohl | RSU | 25,801 | — | 231,951 |
| John Leonard | PSU | 28,397 | — | 255,289 |
| Edward Dulac | PSU | 30,000 | — | 269,700 |
| John Leonard | RSU | 30,346 | — | 272,811 |
| John Leonard | PSU | 34,000 | — | 305,660 |
| James Basta | PSU | 35,211 | — | 316,547 |
| David Lebwohl | PSU | 36,742 | — | 330,311 |
| Birgit Schultes | RSU | 37,600 | — | 338,024 |
| James Basta | RSU | 40,000 | — | 359,600 |
| David Lebwohl | RSU | 43,200 | — | 388,368 |
| Edward Dulac | RSU | 44,216 | — | 397,502 |
| Edward Dulac | RSU | 47,200 | — | 424,328 |
| Edward Dulac | Option | 51,037 | 25.33 | — |
| Birgit Schultes | Option | 53,714 | 10.09 | — |
| James Basta | Option | 57,143 | 10.09 | — |
| John Leonard | Option | 59,197 | 32.66 | — |
| David Lebwohl | Option | 61,714 | 10.09 | — |
| Edward Dulac | Option | 67,429 | 10.09 | — |
| John Leonard | RSU | 75,724 | — | 680,759 |
| John Leonard | PSU | 107,164 | — | 963,404 |
| John Leonard | RSU | 136,000 | — | 1,222,640 |
| John Leonard | Option | 196,000 | 10.09 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank VerwielIndependent | $100,000 | $66,960 | $65,740 | — | — | $232,700 |
| William ChaseIndependent | 72,500 | 66,960 | 65,740 | — | — | 205,200 |
| Brian GoffIndependent | 63,740 | 66,960 | 65,740 | — | — | 196,440 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $236,240 |
| Equity awards (grant-date value) | $200,880 |
| All other compensation | $0 |
| Total cost of the board | $437,120 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Intellia Therapeutics as a peer
Companies that benchmark against NTLA
17 companies name NTLA as a compensation peer
The list of companies that name NTLA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
SANA Sana Biotechnology, Inc.IDYA IDEAYA Biosciences, Inc.RCKT Rocket Pharmaceuticals, Inc.ARWR Arrowhead Pharmaceuticals, Inc.BEAM Beam Therapeutics Inc.BIBR BridgeBio Pharma, Inc.IOVA Iovance Biotherapeutics, Inc.VERV Verve Therapeutics, Inc.CRSP CRISPR Therapeutics AGMDGL Madrigal Pharmaceuticals, Inc.VIR Vir Biotechnology, Inc.DNLI Denali Therapeutics Inc.PRME Prime Medicine, Inc.XNCR Xencor, Inc.RLAY Relay Therapeutics, Inc.ALLO Allogene Therapeutics, Inc.VAXY Vaxcyte, Inc.EDIT Editas Medicine, Inc.IBRX ImmunityBio, Inc.IMVT Immunovant, Inc.
Peer reciprocity
The companies Intellia Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Rocket Pharmaceuticals, Inc. (RCKT)73Arrowhead Pharmaceuticals, Inc. (ARWR)74Beam Therapeutics Inc. (BEAM)75CRISPR Therapeutics AG (CRSP)76Denali Therapeutics Inc. (DNLI)77Relay Therapeutics, Inc. (RLAY)78
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant, Inc. | 2026 | Eric Venker | $636,618 | $0 | $19,010,639 | $0 | $20,158,767 |
| 2 | Madrigal Pharmaceuticals, Inc. | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 3 | ImmunityBio, Inc. | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 4 | Ideaya Biosciences, Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 5 | Arrowhead Pharmaceuticals, Inc. | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 6 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 7 | Crispr Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 8 | Verve Therapeutics, Inc. | 2024 | Sekar Kathiresan | 639,231 | 1,683,000 | 4,727,372 | 378,972 | 7,442,663 |
| 9 | Allogene Therapeutics, Inc. | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 10 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| 11 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 12 | Intellia Therapeutics, Inc. | 2025 | John Leonard | 708,000 | 2,443,920 | 1,356,320 | 0 | 5,063,899 |
| 13 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 14 | Relay Therapeutics, Inc. | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 15 | Prime Medicine, Inc. | 2025 | Allan Reine | 606,212 | 0 | 2,828,798 | 402,000 | 3,894,187 |
| 16 | Rocket Pharmaceuticals, Inc. | 2025 | Gaurav Shah | 671,076 | 806,751 | 1,613,377 | 403,048 | 3,510,241 |
| 17 | Sana Biotechnology, Inc. | 2025 | Steven Harr | 696,140 | 425,001 | 1,327,500 | 450,369 | 2,903,010 |
| 18 | Editas Medicine, Inc. | 2025 | Gilmore O'Neill | 686,574 | 0 | 1,282,937 | 375,164 | 2,353,655 |
| 19 | Iovance Biotherapeutics, Inc. | 2025 | Frederick Vogt | 800,000 | 759,375 | 0 | 312,000 | 1,888,175 |
| — | BridgeBio Pharma, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Vaxcyte, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | 115% | Option 40 · RSU 40 · PSU 20 | Yes — TSR relative to the Nasdaq Biotechnology Index | Alpine |
| Allogene Therapeutics, Inc. | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Arrowhead Pharmaceuticals, Inc. | 125% | PRSU 70 · RSU 30 | not disclosed | Compensia |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| BridgeBio Pharma, Inc. | not disclosed | RSU 50 · PSU 35 · Option 15 | not disclosed | Aon |
| Crispr Therapeutics AG | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Editas Medicine, Inc. | 91% | Options 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Ideaya Biosciences, Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| ImmunityBio, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Immunovant, Inc. | 110% | not disclosed | No | Compensia |
| Iovance Biotherapeutics, Inc. | 60% | not disclosed | No | Haigh & Company |
| Madrigal Pharmaceuticals, Inc. | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Prime Medicine, Inc. | 120% | not disclosed | not disclosed | Alpine Rewards |
| Relay Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon |
| Rocket Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Semler Brossy |
| Sana Biotechnology, Inc. | 107.5% | not disclosed | not disclosed | Aon plc (Human Capital Solutions practice) |
| Vaxcyte, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Verve Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford Data & Analytics from Aon plc |
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 44,806,637 | 13,821,404 | 110,447 | 76.43% | Passed |
| 2025 | 2025-06-11 | 45,766,969 | 18,643,930 | 103,159 | 71.05% | Passed |
| 2024 | 2024-06-12 | 70,436,308 | 1,525,957 | 84,135 | 97.77% | Passed |
| 2023 | 2023-06-14 | 65,818,316 | 1,228,360 | 83,443 | 98.17% | Passed |
| 2022 | 2022-06-14 | 56,825,061 | 1,408,215 | 65,134 | 97.58% | Passed |
| 2021 | 2021-06-23 | 51,721,780 | 1,157,074 | 64,146 | 97.81% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 76.43%a |
| 2025 | 2025-06-11 | 71.05%b |
| 2024 | 2024-06-12 | 97.77%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast for or against this proposal and will accordingly have no effect on the election of the nominees.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast for or against this proposal and will accordingly have no effect on the election of the nominees.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on Proposal No.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 17 : 1 |
|---|---|
| CEO total compensation | $5,063,899 |
| Median employee compensation | $301,044 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Muna Bhanji | Director | 2026-06-09 | A | 13,300 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Brian Goff | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Jesse Goodman | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jesse Goodman | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Georgia Keresty | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Verwiel | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Verwiel | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Muna Bhanji | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Brian Goff | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Georgia Keresty | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| William Chase | Director | 2026-06-09 | A | 13,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Chase | Director | 2026-06-09 | A | 9,200 | 0 | 0 | Common | Form 4 ↗ |
| Michael P. Dube | VP, Chief Accounting Officer | 2026-07-01 | D | 2,641 | 17 | 44,316 | Common | Form 4 ↗ |
| Edward Dulac | EVP, Chief Financial Officer | 2026-07-02 | D | 4,677 | 18 | 84,186 | Common | Form 4 ↗ |
| Edward Dulac | EVP, Chief Financial Officer | 2026-07-22 | D | 8,111 | 11 | 91,249 | Common | Form 4 ↗ |
| John Leonard | Director | 2026-08-20 | D | 19,890 | 13 | 250,614 | Common | Form 4 ↗ |
| John Leonard | Director | 2026-08-21 | D | 2,785 | 13 | 36,205 | Common | Form 4 ↗ |
| Michael P. Dube | VP, Chief Accounting Officer | 2026-10-02 | D | 1,864 | 12 | 23,170 | Common | Form 4 ↗ |
| Jing L. Marantz | EVP, Chief Medical Officer | 2026-10-26 | A | 275,061 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jing L. Marantz | EVP, Chief Medical Officer | 2026-10-26 | A | 199,822 | 0 | 0 | Common | Form 4 ↗ |
| John Leonard | Director | 2026-11-02 | D | 9,000 | 12 | 107,910 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (78 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Leonard. DEF 14A, filed 2026-04-30. Section “2025 Summary Compensation Table” · page 35. As printed: 5,063,899. View filing ↗
- Section 01, Edward Dulac. DEF 14A, filed 2026-04-30. Section “2025 Summary Compensation Table”. As printed: 2,168,505. View filing ↗
- Section 01, David Lebwohl. DEF 14A, filed 2026-04-30. Section “2025 Summary Compensation Table”. As printed: 1,984,724. View filing ↗
- Section 01, James Basta. DEF 14A, filed 2026-04-30. Section “2025 Summary Compensation Table”. As printed: 1,846,597. View filing ↗
- Section 01, Birgit Schultes. DEF 14A, filed 2026-04-30. Section “2025 Summary Compensation Table”. As printed: 1,740,083. View filing ↗
- Section 03, Edward Dulac PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Edward Dulac RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Lebwohl RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, James Basta PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Leonard PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Edward Dulac OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Birgit Schultes PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Lebwohl PSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Leonard RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, James Basta RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Birgit Schultes RSU. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Leonard OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, James Basta OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, David Lebwohl OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Birgit Schultes OPTION. DEF 14A, filed 2026-04-30. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-30. Section “CEO Pay Ratio”. As printed: 17 : 1. View filing ↗
- Section 08, Frank Verwiel. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 232,700. View filing ↗
- Section 08, William Chase. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 205,200. View filing ↗
- Section 08, Brian Goff. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 196,440. View filing ↗
- Section 02, Muna Bhanji 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred E. Cohen 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred E. Cohen 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Goff 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jesse Goodman 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jesse Goodman 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Georgia Keresty 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Verwiel 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Verwiel 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Muna Bhanji 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Goff 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Georgia Keresty 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Chase 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Chase 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael P. Dube 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Dulac 2026-07-02. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Dulac 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Leonard 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Leonard 2026-08-21. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael P. Dube 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jing L. Marantz 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jing L. Marantz 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Leonard 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 76.43% (votes for as printed: 44,806,637). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 71.05% (votes for as printed: 45,766,969). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-13. Item 5.07 · say-on-pay result. As reported: 97.77% (votes for as printed: 70,436,308). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 236,240 + equity 200,880 + all other 0 = 437,120, summed across the director compensation table rows.
- Immunovant, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. View filing ↗
- ImmunityBio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. View filing ↗
- Ideaya Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences, Inc.'s own proxy. As printed: 9,512,640. View filing ↗
- Arrowhead Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. View filing ↗
- Vir Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. View filing ↗
- Crispr Therapeutics AG, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics AG's own proxy. As printed: 7,678,477. View filing ↗
- Verve Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. View filing ↗
- Allogene Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics, Inc.'s own proxy. As printed: 6,136,093. View filing ↗
- Beam Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. View filing ↗
- Xencor, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Intellia Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Relay Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics, Inc.'s own proxy. As printed: 4,646,454. View filing ↗
- Prime Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. View filing ↗
- Rocket Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Rocket Pharmaceuticals, Inc.'s own proxy. As printed: 3,510,241. View filing ↗
- Sana Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sana Biotechnology, Inc.'s own proxy. As printed: 2,903,010. View filing ↗
- Editas Medicine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. View filing ↗
- Iovance Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. View filing ↗
- Section 10a, Rocket Pharmaceuticals, Inc. reciprocity. DEF 14A. Rocket Pharmaceuticals, Inc. names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocity. DEF 14A. Arrowhead Pharmaceuticals, Inc. names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Beam Therapeutics Inc. reciprocity. DEF 14A. Beam Therapeutics Inc. names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, CRISPR Therapeutics AG reciprocity. DEF 14A. CRISPR Therapeutics AG names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Denali Therapeutics Inc. reciprocity. DEF 14A. Denali Therapeutics Inc. names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Relay Therapeutics, Inc. reciprocity. DEF 14A. Relay Therapeutics, Inc. names Intellia Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗